Work

E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.tps3665

Authors: Howard S. Hochster, Paul J. Catalano, Edith P. Mitchell, Deirdre Jill Cohen, Peter J. O'Dwyer, Al Bowen Benson, ECOG

Institutions: Yale University, Dana-Farber Cancer Institute, Thomas Jefferson University, Sidney Kimmel Cancer Center, New York University, Abramson Cancer Center, University of Pennsylvania, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4256400180

Cites:

Cited by: 2

Related to: 10